408 results on '"Silverman, Stuart L."'
Search Results
2. Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk
3. Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures
4. Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
5. Economic and Humanistic Burden Among Medicare-Aged Women With Fragility Fracture in the United States
6. Evaluation of a Multimodal, Direct‐to‐Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial
7. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood
8. A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material
9. The Utility and Limitations of FRAX: A US Perspective
10. Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies
11. New Selective Estrogen Receptor Modulators (SERMs) in Development
12. Anabolic Therapies
13. Conclusions
14. A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material
15. 199 - Clinical evaluation and clinical features of osteoporosis
16. Understanding Physicians’ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach
17. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
18. Individualizing Osteoporosis Therapy
19. Burden of Fibromyalgia and Comparisons With Osteoarthritis in the Workforce
20. Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT
21. Commentary: The Five Ws of a Fracture Liaison Service: Why, Who, What, Where, and How? In Osteoporosis, We Reap What We Sow
22. The Utility of Changes in Serum Levels of C-Terminal Telopeptide of Type I Collagen in Predicting Patient Response to Oral Monthly Ibandronate Therapy
23. Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data
24. Commentary: Measuring Quality of Care in Osteoporosis
25. Potential Drug–Drug and Drug–Condition Interactions among Fibromyalgia Patients Initiating Pregabalin or Duloxetine: Prevalence and Health Care Expenditure Impact
26. New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab
27. Glucocorticoid-induced osteoporosis
28. Compliance and persistence with osteoporosis therapies
29. Osteonecrosis of the jaws and bisphosphonates
30. Cost comparison of drug–drug and drug–condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine
31. Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?
32. Selecting patients for osteoporosis therapy
33. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study
34. Quality-of-life issues in osteoporosis
35. Increasing hip fracture incidence in California Hispanics, 1983 to 2000
36. Contributors
37. Adverse Health Outcomes in Men with Osteoporosis
38. Contributors
39. Lessons from osteoporosis clinical trials
40. The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis
41. The impact of ‘best-practice’ patient care in fibromyalgia on practice economics
42. Evaluation of Risk for Osteoporotic Fracture
43. Real-World Evaluation of Health-Care Resource Utilization and Costs in Employees with Fibromyalgia Treated with Pregabalin or Duloxetine
44. Bisphosphonate use in conditions other than osteoporosis
45. Identifying Fibromyalgia-Associated Symptoms and Conditions from a Clinical Perspective: A Step Toward Evaluating Healthcare Resource Utilization in Fibromyalgia
46. Bisphosphonates and Atypical Femoral Fractures
47. Contributors
48. Calcitonin in the Treatment of Osteoporosis
49. Nasal calcitonin
50. Paget Disease of Bone: Therapeutic Options
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.